...
首页> 外文期刊>American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons >Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning.
【24h】

Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning.

机译:Treg疗法无需细胞还原性调节即可实现混合嵌合和移植耐受性。

获取原文
获取原文并翻译 | 示例

摘要

Establishment of mixed chimerism through transplantation of allogeneic donor bone marrow (BM) into sufficiently conditioned recipients is an effective experimental approach for the induction of transplantation tolerance. Clinical translation, however, is impeded by the lack of feasible protocols devoid of cytoreductive conditioning (i.e. irradiation and cytotoxic drugs/mAbs). The therapeutic application of regulatory T cells (Tregs) prolongs allograft survival in experimental models, but appears insufficient to induce robust tolerance on its own. We thus investigated whether mixed chimerism and tolerance could be realized without the need for cytoreductive treatment by combining Treg therapy with BM transplantation (BMT). Polyclonal recipient Tregs were cotransplanted with a moderate dose of fully mismatched allogeneic donor BM into recipients conditioned solely with short-course costimulation blockade and rapamycin. This combination treatment led to long-term multilineage chimerism and donor-specific skin graft tolerance. Chimeras also developed humoral and in vitro tolerance. Both deletional and nondeletional mechanisms contributed to maintenance of tolerance. All tested populations of polyclonal Tregs (FoxP3-transduced Tregs, natural Tregs and TGF-beta induced Tregs) were effective in this setting. Thus, Treg therapy achieves mixed chimerism and tolerance without cytoreductive recipient treatment, thereby eliminating a major toxic element impeding clinical translation of this approach.
机译:通过将同种异体供体骨髓(BM)移植到条件充分的受体中来建立混合嵌合体是诱导移植耐受性的有效实验方法。但是,由于缺乏缺乏细胞还原条件的可行方案(即放射线和细胞毒性药物/ mAb),阻碍了临床翻译。调节性T细胞(Tregs)的治疗应用可以延长同种异体移植物在实验模型中的存活率,但似乎不足以单独诱导出强大的耐受性。因此,我们研究了通过将Treg治疗与BM移植(BMT)结合使用,是否可以在无需进行细胞还原治疗的情况下实现混合嵌合和耐受性。将多克隆受体Treg与中等剂量的完全错配的同种异体供体BM共移植到仅接受短程共刺激阻断和雷帕霉素治疗的受体中。这种联合治疗导致长期多系嵌合和供体特异性皮肤移植耐受性。嵌合体还发展了体液和体外耐受性。删除和非删除机制都有助于维持耐受性。在这种情况下,所有测试的多克隆Treg(FoxP3转导的Treg,天然Treg和TGF-β诱导的Treg)种群均有效。因此,Treg疗法无需细胞还原受体治疗即可达到混合的嵌合体和耐受性,从而消除了阻碍该方法临床翻译的主要毒性元素。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号